• June 10, 2024

Nasal powders have been recognized as an opportunity to improve stability and residence time on the nasal mucosa compared with liquids, where amorphous powders favor the formulation of poorly soluble drugs with improved biopharmaceutical profile, namely faster onset of action. This article presents two case studies focused on particle engineering strategies and nasal powder formulation […]

Nasal powder formulations represent a significant stride in drug delivery innovation, offering the potential for simplified, preservative-free compositions. Increased chemical stability and enhanced capacity for higher drug loads are additional benefits offered by formulating as a dry powder. Application of established production technologies, such as spray drying, allows for the design and manufacture of readily […]

  • April 5, 2024

This article describes the development and validation of the Alberta Idealised Nasal Inlet (AINI), illustrating its use within existing test set-ups. It also discusses three experimental studies that demonstrate: 1) the ability of the AINI to capture in vivo deposition behavior for different nasal drug products, 2) use of the AINI to assess and optimize […]

Oddly missing from the pharmacopeial compendia and archival literature are flow resistance data for glass microfiber filters common to the delivered dose uniformity (DDU) testing protocols described in the USP and European Pharmacopeias. The authors undertook a laboratory investigation to provide insight into how filter flow resistance can vary across several similar products available commercially. […]

The Association of Inhalation Toxicologists (AIT) presented a workshop at the 2023 Drug Delivery to the Lungs Conference. The focus was on methods used for in vitro toxicity screening, in vivo study designs, toxicological endpoints and regulatory toxicology. The workshop also covered technical aspects of the generation, characterization and dosimetry of aerosols in toxicology studies. […]

  • February 14, 2024

There has been a surge in interest surrounding the development of carrier-free dry powder formulations intended for pulmonary drug delivery. Spray drying is the preferred technique for the production of carrier-free dry powder formulations. Shell-forming excipients can play a pivotal role in overcoming challenges related to spray drying including particle cohesion, hygroscopicity and overall stability. […]

We investigated how the change from current generation to next-generation pMDI propellants might affect the technical performance of currently used pMDI hardware, with a focus on actuator designs that assist with achievement of in vitro equivalence. The key finding of the preliminary in vitro studies described is that the changes required to convert pMDI formulations […]

  • December 1, 2023

In the first article, we explored the robustness of the pharmacopeial methodology for the determination of delivered dose uniformity (DDU) for orally inhaled products to bias in volumetric flow rate setting from variations in ambient pressure. In this article, we extend the analysis to evaluate how the determination of the second performance-related critical quality attribute, […]

This article discusses development of polymeric nanoparticles intended to obtain optimal features for loading therapeutic antibodies and be formulated into dry powders for inhalable lung cancer treatment. This may reduce serious side effects and toxicity and support therapeutic adherence, effectiveness and safety. The article also discusses dry powder formulation with respect to particle deposition profile […]

  • October 17, 2023

In 2020 and 2021, Inhalation published three articles by the Cascade Impaction Working Group of the International Pharmaceutical Aerosol Consortium for Regulation and Science (IPAC-RS): (1) The liability of fine particle dose (FPD); (2) Cascade impactor stage groupings: Poor decisions from degraded data; and (3) Efficient data analysis (EDA): Size, mass and common sense. In […]